Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 1
2013 2
2014 1
2016 2
2017 1
2018 4
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
TET2, a tumor suppressor in hematological disorders.
Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard OA. Mercher T, et al. Among authors: quivoron c. Biochim Biophys Acta. 2012 Apr;1825(2):173-7. doi: 10.1016/j.bbcan.2011.12.002. Epub 2012 Jan 3. Biochim Biophys Acta. 2012. PMID: 22240200 Review.
B-cell tumor development in Tet2-deficient mice.
Mouly E, Ghamlouch H, Della-Valle V, Scourzic L, Quivoron C, Roos-Weil D, Pawlikowska P, Saada V, Diop MK, Lopez CK, Fontenay M, Dessen P, Touw IP, Mercher T, Aoufouchi S, Bernard OA. Mouly E, et al. Among authors: quivoron c. Blood Adv. 2018 Mar 27;2(6):703-714. doi: 10.1182/bloodadvances.2017014118. Blood Adv. 2018. PMID: 29581109 Free PMC article.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, El-Dakdouki Y, Goldschmidt V, Bigenwald C, Dragani M, Bahleda R, Baldini C, Arfi-Rouche J, Martin-Romano P, Tselikas L, Gazzah A, Hollebecque A, Lacroix L, Ghez D, Vergé V, Marzac C, Cotteret S, Rahali W, Soria JC, Massard C, Bernard OA, Dartigues P, Camara-Clayette V, Ribrag V. Michot JM, et al. Among authors: quivoron c. Am J Hematol. 2023 Apr;98(4):645-657. doi: 10.1002/ajh.26835. Epub 2023 Jan 18. Am J Hematol. 2023. PMID: 36606708 Free article.
JAK2V⁶¹⁷F/TET2 mutations: does the order matter?
Pronier E, Quivoron C, Bernard OA, Villeval JL. Pronier E, et al. Among authors: quivoron c. Haematologica. 2011 May;96(5):638-40. doi: 10.3324/haematol.2011.042846. Haematologica. 2011. PMID: 21531945 Free PMC article. No abstract available.
Endothelial and hematopoietic hPSCs differentiation via a hematoendothelial progenitor.
Vargas-Valderrama A, Ponsen AC, Le Gall M, Clay D, Jacques S, Manoliu T, Rouffiac V, Ser-le-Roux K, Quivoron C, Louache F, Uzan G, Mitjavila-Garcia MT, Oberlin E, Guenou H. Vargas-Valderrama A, et al. Among authors: quivoron c. Stem Cell Res Ther. 2022 Jun 17;13(1):254. doi: 10.1186/s13287-022-02925-w. Stem Cell Res Ther. 2022. PMID: 35715824 Free PMC article.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Quivoron C, Tarabay A, Michot JM, Pagès A, Lecourt H, Aupérin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C. Quivoron C, et al. Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464. Haematologica. 2022. PMID: 35320922 Free PMC article. No abstract available.
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P. Quek L, et al. Among authors: quivoron c. Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16. Nat Med. 2018. PMID: 30013198 Free PMC article.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Sarkozy C, Michot JM, Quivoron C, Camara-Clayette V, Danu A, Lazarovici J, El-Dakdouki Y, Saleh K, Ghez D, Rossignol J, Baldini C, Arfi-Rouche J, Romano-Martin P, Tselikas L, Varga A, Gazzah A, Hollebecque A, Lacroix L, Bahleda R, Lecourt H, Vergé V, Rahali W, Cotteret S, Soria JC, Dartigues P, Massard C, Ribrag V. Sarkozy C, et al. Among authors: quivoron c. Am J Hematol. 2021 Oct 1;96(10):E376-E379. doi: 10.1002/ajh.26280. Epub 2021 Jul 10. Am J Hematol. 2021. PMID: 34165816 Free article. Clinical Trial. No abstract available.
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.
Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, De Botton S. Willekens C, et al. Among authors: quivoron c. Leukemia. 2018 Sep;32(9):2008-2081. doi: 10.1038/s41375-018-0056-6. Epub 2018 Feb 26. Leukemia. 2018. PMID: 29479068 No abstract available.
19 results